Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company. Through its subsidiary, the company is engaged in developing and commercializing cancer immunotherapies in the United States. The company is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody.
  • TickerRCUS
  • ISINUS03969F1093
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Jonathan Moreland

InsiderInsights Weekly Tables: July 6, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Jonathan Moreland

InsiderInsights Weekly Tables: July 6, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Jonathan Moreland

InsiderInsights Weekly Tables: June 29, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ValuEngine Rating and Forecast Report for RCUS

ResearchPool Subscriptions

Get the most out of your insights

Get in touch